Treatment of Advanced Non-Small-Cell Lung Cancer Patients with ECOG Performance Status 2: Results of a European Experts Panel

    loading  Checking for direct PDF access through Ovid

Abstract

Synopsis:

Single-agent chemotherapy should be the standard arm against which experimental treatments are tested in randomised trials dedicated to PS2 patients. High priority should be given to the evaluation of tolerability and efficacy of platinum-based combinations, and to the testing of new biological agents. Another research priority is the improvement of supportive care. Patients strongly need symptomatic improvement: end points such as symptom relief, clinical benefit and quality of life should have a central position in trials dedicated to PS2 NSCLC patients.

Related Topics

    loading  Loading Related Articles